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Summary
Vulvar cancer is a rare disease among young women. Risk factors for vulvar cancer are smoking, chronic dermatitis 
and human papilloma virus infection. However, no correlation between multiple sclerosis and increased risk of cancer has 
been established.
We present a case of vulvar cancer in 35 year old women with multiple sclerosis. Radical vulvectomy with right-sided 
inguinofemoral lymphadenectomy was performed. Pathohistological analysis confi rmed the diagnosis of a squamous cell 
carcinoma, grade II, International Federation of Gynecology and Obstetrics (FIGO) IB. Adjuvant radiotherapy was not indi-
cated. After two years of follow up, there was no evidence of the recurrence. 
The occurrence of vulvar cancer in multiple sclerosis patients may be coincidental. Nevertheless, the long term use of 
immunomodulatory drugs in multiple sclerosis and incidence of cancer may be associated.
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KARCINOM STIDNICE KOD MLADE ŽENE I TERAPIJA MULTIPLE SKLEROZE: 
PRIKAZ SLUČAJA
Sažetak
Karcinom stidnice je rijetka bolest u mladih žena. Rizični faktori za karcinom stidnice su pušenje, kronični dermatitis 
i infekcija humanim papiloma virusom. Nije dokazana povezanost između multiple skleroze i povećanog rizika za razvoj 
karcinoma.
Opisujemo slučaj karcinoma stidnice u 35-godišnje žene koja boluje od multiple skleroze. Učinjena je radikalna vul-
vektomija s desnostranom ingvinofemoralnom limfadenektomijom. Patohistološka analiza potvrdila je dijagnozu planoce-
lularnog karcinoma, gradus II, FIGO 1B. Adjuvantna radioterapija nije bila indicirana. Nakon dvije godine praćenja, nema 
znakova povrata bolesti.
Pojava karcinoma stidnice u mlade bolesnice s multiplom sklerozom, može biti koincidencija. Moguća je povezanost 
dugotrajnog korištenja imunomodulatornih lijekova u multiploj sklerozi i incidencije karcinoma.
KLJUČNE RIJEČI: karcinom stidnice, multipla skleroza, faktori rizika, prikaz slučaja
INTRODUCTION
Vulvar cancer makes fi ve percent of malig-
nancies of the female genital tract and is the fourth 
most common gynecologic cancer. Within the 
United States, almost 4900 cases are diagnosed 
each year (1). Vulvar cancer usually occurs in 
post-menopausal period in the seventh and eighth 
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decade of life (1, 2). However, the average age of 
occurrence of vulvar cancer seems to have moved 
from 69 to 55 years from 1979 to 1993 (3). Women 
who develop the disease before turning 40 mostly 
have one of the risk factors, such as smoking, 
chronic dermatitis and human papilloma virus 
(HPV) infection (4, 5). Most of them have microin-
vasive vulvar cancer with vulvar intraepithelial 
neoplasia (VIN). The most common type of cancer 
is squamous cell carcinoma, which emerges on la-
bia majora in over 60% of cases (6). 
The correlation between cancer and autoim-
mune diseases has not been completely elucidated 
(7). Increased relative risk of carcinoma among 
patients with systemic lupus erythematosus, 
rheumatoid arthritis and systemic sclerosis, with 
prominent risk for lymphoproliferative malignant 
diseases has been recorded (8-12). Multiple sclero-
sis (MS) is an autoimmune diseases primarily of 
the central nervous system and there is no data on 
increased risk of cancer in MS patients. It most 
commonly aff ects women at the ages 20 to 40 (2). 
Furthermore, the possibility of constant stimula-
tion of the immune system which inhibits carci-
nogenesis and thus decreases the incidence of 
 cancer among the patients with MS was suggested 
(13). On the other hand, eff ects of MS treatment 
on cancer incidence seems to be less straight for-
ward (14).
CASE REPORT
A 35-year-old patient with no family history 
and 15 years of treatment for multiple sclerosis, 
underwent work up for pain in the vulvar area 
and no other symptoms. Unphysical examination 
an exulcerated tumor formation (about 3 cm in di-
ameter) in the posterior area of the right labia ma-
jora was recorded. The formation was hard but 
not fi xed to the surrounding structures. A biopsy 
was performed and squamous cell carcinoma, 
grade II was confi rmed. Reviewing patient’s his-
tory, we founded that patient was also diagnosed 
with multiple sclerosis at the age of 20. The fi rst 
manifestation of the disease was pain in the right 
eye and optical neuritis was diagnosed. She had 
ten relapses so far which were manifested as the 
paralysis of the right side of her body, dizziness 
and as optic neuritis on both eyes. Initially, the re-
lapses occurred twice a year and then later once a 
year. Since four years ago, there have been no ma-
jor signs of deterioration except for a temporary 
case of dysphagia. In the initial stages of the dis-
ease, the patient received 15 doses of immuno-
globulin in monthly doses of 5 g. Six years ago, the 
patient started her interferon treatment which she 
took for two years. For the past four years, she had 
been taking laquinimod, immunomodulator in 
the dosage of 0,5 mg. She stopped taking laquiniq-
mod before the surgery. She has been regularly 
consultated by her neurologist.
Radical vulvectomy with right-sided ingu-
inofemoral lymphadenectomy was indicated. Op-
eration and the post-operative period were un-
eventful. The patient was discharged on her 10th 
postoperative day. Taking the size of the tumor 
into consideration, the distance of resection edges 
from the tumor and considering the fact that no 
tumor infi ltrates were found in the removed 
lymph nodes, no adjuvant radiotherapy was indi-
cated. After two years of follow up, there is no 
evidence of the disease in our patient. During the 
follow-up period patient continued taking a laqui-
nimod. 
DISCUSSION
Vulvar cancer is rare at young age and mul-
tiple sclerosis as a comorbidity should decrease 
the risk of having a carcinoma. However, treat-
ment for multiple sclerosis might be increasing 
the very risk.
Our patient was diagnosed with vulvar can-
cer at the age of 35, which is under the expected 
age for this type of cancer. However there is a de-
creasing median age of diagnosis over the past 
few decades (13). Moreover, vulvar cancer among 
young women was most commonly related to ex-
isting VIN and/or smoking as a risk factor (4, 5). 
These risk factors were not present in our patient. 
As for the symptoms, the patient did not experi-
ence itching, the most common one, but only pain 
in the region. Pain, discharge and bleeding are less 
common symptoms (7). This might be associated 
with MS.
Protective eff ect of constant activity of the 
immune system in autoimmune diseases and cor-
relation between therapy for multiple sclerosis 
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and incidence of cancer was researched (13, 14, 
15). Israeli study, compared the cancer incidence 
among the population with multiple sclerosis and 
general standardized population in the period 
from 1960 to 2003, showing that the incidence of 
cancer among women with multiple sclerosis was 
lower. The treatment scheme was also analysed. 
The patients were treated with glatiramer acetate, 
β-interferons and intravenous immunoglobulin. 
Patients treated with glatiramer acetate had a 
higher incidence of breast cancer development, 
while those that received β-interferons had a high-
er incidence of development of other cancer sites, 
but not statistically signifi cant (15). Our patient 
took corticosteroids in acute att acks in the initial 
stages of the disease, and she later used β-in-
terferons and fi nally laquinimod. Laqunimod has 
been turned down two times by the European 
Medicines Agency’s Committ ee for Medicinal 
Products for Human Use because of concerns 
about possible teratogenic eff ects and cancer in 
animal studies of long-term exposure to laquini-
mod (16). The latest research, however, showed 
that there was no increase in the incidence of ma-
lignancies in long term use of laquinimod (16, 17). 
Our patient was taking laquinimod for four years 
prior to surgery. 
Surgery is the mainstay of the treatment for 
vulvar cancer. Therefore, radical vulvectomy with 
right-sided inquinofemoral lymphadenectomy 
was performed. Omission of lymphadenectomy is 
allowed only when tumor stromal invasion is ≤ 1 
mm. An unilateral lymphadenectomy is per-
formed only in well-lateralized early lesions, 
which was the case with our patient (18). Patho-
logic status of the inguinal nodes and aff ection of 
adjacent structures are most important factors de-
termining survival and prognosis while the size of 
the primary tumor is not so important (19). In op-
erable patients with disease negative lymph 
nodes, the overall survival (OS) rate is 90%, com-
pared with patients with positive lymph nodes, 
the 5-year OS rate is about 50% to 60% (20). 
CONCLUSION
Patient with multiple sclerosis may require 
additional att ention due to eff ect of their therapy 
and lack of symptoms when malignant gyneco-
logical tumors are considered. Timely surgery 
provides good disease control.
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